Click here for more information about Aldesleukin [clinicaltrials_resource:bb8f0a4aaa91e5d3f483342a43a01a1a]
A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC [clinicaltrials:NCT00000680]Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy [clinicaltrials:NCT00000728]A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy [clinicaltrials:NCT00000820]Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients [clinicaltrials:NCT00000821]The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 [clinicaltrials:NCT00000825]A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone [clinicaltrials:NCT00000870]Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection [clinicaltrials:NCT00000875]A Study to Evaluate the Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 [clinicaltrials:NCT00000889]Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328 [clinicaltrials:NCT00000923]The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients With AIDS or AIDS Related Complex [clinicaltrials:NCT00000986]A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes [clinicaltrials:NCT00001005]Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients [clinicaltrials:NCT00001131]clinicaltrials:NCT00004978Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems [clinicaltrials:NCT00006066]Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination [clinicaltrials:NCT00006291]Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy [clinicaltrials:NCT00038259]Safety and Effectiveness of Immunotherapy With Autologous HIV-Specific CD8 Cells in HIV Infected Adults [clinicaltrials:NCT00110578]
link [clinicaltrials_vocabulary:link]
Click here for more information about Aldesleukin [clinicaltrials_resource:bb8f0a4aaa91e5d3f483342a43a01a1a]
Bio2RDF identifier
bb8f0a4aaa91e5d3f483342a43a01a1a
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:bb8f0a4aaa91e5d3f483342a43a01a1a
url [clinicaltrials_vocabulary:url]
identifier
clinicaltrials_resource:bb8f0a4aaa91e5d3f483342a43a01a1a
title
Click here for more information about Aldesleukin
@en
Click here for more information on aldesleukin
@en
type
label
Click here for more informatio ...... f0a4aaa91e5d3f483342a43a01a1a]
@en
Click here for more informatio ...... f0a4aaa91e5d3f483342a43a01a1a]
@en